Berkshire Bank Makes New $202,000 Investment in Zoetis Inc. (NYSE:ZTS)

Berkshire Bank purchased a new stake in shares of Zoetis Inc. (NYSE:ZTS) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 1,241 shares of the company’s stock, valued at approximately $202,000.

Other large investors have also made changes to their positions in the company. Darwin Wealth Management LLC bought a new stake in Zoetis in the third quarter worth approximately $31,000. First Personal Financial Services acquired a new stake in shares of Zoetis in the 3rd quarter valued at $33,000. Capital Performance Advisors LLP bought a new stake in Zoetis in the third quarter worth $33,000. Dunhill Financial LLC increased its position in Zoetis by 80.6% during the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after buying an additional 75 shares during the last quarter. Finally, Quarry LP increased its position in Zoetis by 273.2% during the second quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after buying an additional 153 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

NYSE:ZTS opened at $173.07 on Tuesday. The firm’s 50-day moving average is $170.10 and its 200-day moving average is $179.75. The company has a market cap of $78.08 billion, a price-to-earnings ratio of 32.53, a PEG ratio of 2.57 and a beta of 0.89. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $200.53.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The firm had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.29 billion. During the same period in the previous year, the company posted $1.36 earnings per share. The company’s quarterly revenue was up 11.6% compared to the same quarter last year. Equities research analysts anticipate that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, January 21st will be paid a dividend of $0.50 per share. The ex-dividend date is Tuesday, January 21st. This represents a $2.00 dividend on an annualized basis and a yield of 1.16%. This is an increase from Zoetis’s previous quarterly dividend of $0.43. Zoetis’s payout ratio is currently 37.59%.

Analysts Set New Price Targets

Several analysts have recently issued reports on ZTS shares. UBS Group began coverage on Zoetis in a research note on Monday, December 9th. They set a “neutral” rating and a $196.00 price target for the company. Leerink Partners started coverage on Zoetis in a report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target on the stock. Stifel Nicolaus dropped their price target on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. JPMorgan Chase & Co. upped their price objective on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Finally, Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. One investment analyst has rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $211.89.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.